Somatuline® Depot (Lanreotide) for Acromegaly Post-Marketing Observational Study

The objectives of this post-marketing observational study are to assess the safety and
effectiveness, as measured by insulin-like growth factor-1 (IGF-1) and growth hormone (GH)
levels, of Somatuline® Depot (lanreotide) Injection when administered by a health care
professional (HCP), the patient, the patient's partner or parent/guardian as part of their
routine acromegaly care. Treatment convenience and acromegaly symptom relief will also be
assessed through questionnaires, and demographic and medical history information will be
collected.

Inclusion Criteria:

- The patient must have a clinical diagnosis of acromegaly

- The patient must be treated with Somatuline® Depot (including patients newly
prescribed Somatuline® Depot)

- The patient or legally authorized representative must be able to understand the
protocol and give signed informed consent. Assent from the patient should also be
obtained, where appropriate. Signed informed consent and assent must be obtained
before any study-related activities are conducted.

Exclusion Criteria:

- Symptomatic, untreated biliary lithiasis

- Known hypersensitivity to somatostatin analogs or related compounds (e.g., octreotide)